ロード中...
Novel targets in aggressive lymphoma
Targeting CD20 with the monoclonal antibody rituximab has improved survival in patients with aggressive B-cell lymphomas, the majority of which are cured with chemoimmunotherapy. Patients progressing through or relapsing after their treatment have a poor prognosis. Despite a number of promising nove...
保存先:
| 出版年: | Hematology Am Soc Hematol Educ Program |
|---|---|
| 第一著者: | |
| フォーマット: | Artigo |
| 言語: | Inglês |
| 出版事項: |
American Society of Hematology
2020
|
| 主題: | |
| オンライン･アクセス: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7727526/ https://ncbi.nlm.nih.gov/pubmed/33275737 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1182/hematology.2020000093 |
| タグ: |
タグ追加
タグなし, このレコードへの初めてのタグを付けませんか!
|